Avidity
In May 2020, Michael MacLean joined Avidity Biosciences as the Chief Financial Officer. Mr. MacLean brings decades of relevant financial industry experience to Avidity, with deep experience in funding biotechnology companies to advance novel therapies in the rare and orphan disease space. Most recently, Mr. MacLean served as Chief Financial Officer of Akcea Therapeutics, Inc. where he led the buildout of Akcea's financial and commercial infrastructure. Prior to Akcea, Mr. MacLean served as Chief Financial Officer of PureTech Health, plc, as well as Chief Accounting Officer of Biogen Inc. where he led the company's worldwide finance operations.
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.